Fenoldopam Mesylate

Inquiry

Cat Number

API0231514

CAS Number

67227-57-0

If you have any other questions, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

67227-57-0

EINECS

266-612-7

Storage

Store at room temperature

Synonyms

Corlopam; Fenoldopam methanesulfonate; Fenoldopam mesilate; SK&F 82526-J; Fendolopam mesylate; NSC-759860; HA3R0MY016

Molecular Formula

C17H20ClNO6S

Molecular Weight

401.9

Smiles

CS(=O)(=O)O.C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O

Appearance

White powder

Melting Point

274℃

Boiling Point

522.6℃

General Description

Fenoldopam mesylate is a synthetic, rapid-acting vasodilator that acts as a selective agonist at dopamine-1 (DA1) receptors. It is administered via continuous intravenous infusion and is characterized by its ultrashort half-life, allowing for rapid titration of hemodynamic effects. This agent is chemically distinct from other antihypertensive agents and exhibits no significant activity at dopamine-2 or adrenergic receptors.

Mechanism of Action

By selectively activating peripheral DA1 receptors located on renal, mesenteric, coronary, and cerebral arteries, fenoldopam stimulates adenylate cyclase and increases intracellular cyclic AMP. This leads to relaxation of vascular smooth muscle and dose-dependent vasodilation. The drug also promotes natriuresis and diuresis through increased renal blood flow and direct tubular effects, distinguishing it from simple vasodilators.

Application

It is indicated for the in-hospital, short-term management of severe hypertension, including hypertensive emergencies and postoperative hypertension. Its rapid onset and short duration make it ideal for situations requiring precise blood pressure control. Additionally, it has been utilized for the prevention of acute kidney injury following cardiac surgery and radiocontrast nephropathy, though such uses remain off-label.

A prospective randomized trial assessed whether fenoldopam, a dopamine‑1 receptor agonist, improves kidney function in 40 dogs with naturally occurring heatstroke‑associated acute kidney injury. Fenoldopam infusion at 0.1 µg/kg/min did not cause hypotension. Mortality rates were similar between fenoldopam (30%) and placebo (40%) groups. No significant differences appeared in urine production, glomerular filtration rate, or sodium fractional excretion.

Fig. 1 Urine production (mean ± SD) over time in dogs sustaining heatstroke, receiving fenoldopam (n = 20) or placebo. (Segev G, et al., 2018)

References

Segev G, et al. Effects of fenoldopam on kidney function parameters and its therapeutic efficacy in the management of acute kidney injury in dogs with heatstroke. J Vet Intern Med. 2018; 32(3):1109-1115.

Does Fenoldopam Mesylate require protection from light during storage?

Yes, it is photosensitive. Exposure to light can cause photodegradation and discoloration. Store in light-resistant containers and handle under subdued light.

What is the recommended storage temperature for Fenoldopam Mesylate?

Store at controlled room temperature, between 20°C and 25°C. Brief excursions are permitted, but avoid excessive heat, which can accelerate oxidation.

Is Fenoldopam Mesylate susceptible to oxidation in aqueous solutions?

Yes, the catechol moiety is prone to oxidation. For intravenous formulations, antioxidants (such as sodium metabisulfite) and pH control (acidic) are required to maintain stability.

How is the impurity profile of Fenoldopam Mesylate monitored for parenteral use?

We use a stability-indicating HPLC method to monitor related compounds, including oxidation products, ensuring they meet strict limits for injectable-grade material.